Ariel Investments LLC - Ariel Global Fund on Pharmaron Beijing Co., Ltd.
Thesis
Pharmaron is positioned to benefit from China's growing role in global biopharma innovation. Its integrated discovery, development and manufacturing platform lets it participate across the drug lifecycle as Chinese biotechnology gains share. Ariel believes regulatory and geopolitical risks are better reflected in valuation while improving orders and operating leverage support the long-term opportunity.
“we believe Pharmaron represents an attractive long-term investment opportunity.”
Key risks
- Regulatory scrutiny
- Geopolitical tensions
- Data integrity concerns